Formulation of RNA-adjuvans and mRNA-vaccins

Nanoparticle platforms for the delivery of RNA adjuvant and mRNA vaccines offer huge potential for innovation in vaccine technology and drug delivery. One of the benefits is the ability of nanoparticles to protect fragile RNA molecules from degradation by nucleases in the body, increasing the stability and longevity of the treatment.

The versatility of nanoparticles enables co-delivery of RNA adjuvant and mRNA vaccines within the same formulation platform. This creates a synergistic effect where the adjuvant enhances the ability of the vaccine to stimulate a robust and durable immune response.

The project aims to strengthen the collaboration between RISE, PAI Life Sciences and HDT Bio on these formulations, to jointly seek long-term funding for the development of RNA delivery systems.

The long-term goal is the development of next-generation carrier particles and adjuvant and RNA formulations for more effective vaccines. The goal is also safer vaccines for a wide range of patients, including those with underlying health conditions that make them more vulnerable to side effects.